Literature DB >> 8140057

Clearance mechanisms of atrial and brain natriuretic peptides in rats.

Y Hashimoto1, K Nakao, N Hama, H Imura, S Mori, M Yamaguchi, M Yasuhara, R Hori.   

Abstract

To assess clearance mechanisms of atrial and brain natriuretic peptides in the circulation, we examined the effects of a neutral endopeptidase (NEP) inhibitor and a clearance receptor ligand on plasma concentrations of the peptides in normal rats. Plasma concentrations of endogenous alpha-rat atrial natriuretic peptide (alpha-rANP) were not significantly elevated by intravenous infusion of a NEP inhibitor, phosphoramidon, but were elevated threefold by intravenous infusion of a clearance receptor ligand, des(Gln18-Gly22)-rANP(4-23)-NH2 [C-ANF(4-23)]. On the other hand, the clearance of alpha-rANP given intravenously at the pharmacological dose, 600 pmol/min/kg for 2 min, was decreased to one-third by the administration of phosphoramidon, although the administration of C-ANF(4-23) did not significantly decrease the clearance. The clearance of rat brain natriuretic peptide (rBNP) given at 600 pmol/min/kg for 2 min was approximately 38% lower than that of alpha-rANP. The effect of phosphoramidon on the clearance of rBNP was not significant and was similar to that of C-ANF(4-23). These results suggest that clearance receptor is involved in the clearance of the physiological levels of alpha-rANP and that NEP plays a major role in the clearance of a pharmacological dose of alpha-rANP, at which clearance receptors are thought to be saturated, and also indicate a pharmacokinetic difference between alpha-rANP and rBNP.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8140057     DOI: 10.1023/a:1018941626731

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  15 in total

1.  Physiological role of silent receptors of atrial natriuretic factor.

Authors:  T Maack; M Suzuki; F A Almeida; D Nussenzveig; R M Scarborough; G A McEnroe; J A Lewicki
Journal:  Science       Date:  1987-10-30       Impact factor: 47.728

2.  Specific receptors for atrial natriuretic polypeptide on basolateral membranes isolated from rat renal cortex.

Authors:  R Hori; K Inui; H Saito; Y Matsukawa; K Okumura; K Nakao; N Morii; H Imura
Journal:  Biochem Biophys Res Commun       Date:  1985-06-28       Impact factor: 3.575

3.  Rat brain natriuretic peptide--tissue distribution and molecular form.

Authors:  Y Ogawa; K Nakao; M Mukoyama; G Shirakami; H Itoh; K Hosoda; Y Saito; H Arai; S Suga; M Jougasaki
Journal:  Endocrinology       Date:  1990-04       Impact factor: 4.736

4.  Urodilatin (CDD/ANP-95-126) is not biologically inactivated by a peptidase from dog kidney cortex membranes in contrast to atrial natriuretic peptide/cardiodilatin (alpha-hANP/CDD-99-126).

Authors:  M Gagelmann; D Hock; W G Forssmann
Journal:  FEBS Lett       Date:  1988-06-20       Impact factor: 4.124

Review 5.  Role of endopeptidase-24.11 in the inactivation of atrial natriuretic peptide.

Authors:  A J Kenny; S L Stephenson
Journal:  FEBS Lett       Date:  1988-05-09       Impact factor: 4.124

6.  The pharmacokinetics of alpha-human atrial natriuretic polypeptide in healthy subjects.

Authors:  K Nakao; A Sugawara; N Morii; M Sakamoto; T Yamada; H Itoh; S Shiono; Y Saito; K Nishimura; T Ban
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

7.  Degradation of atrial natriuretic peptide: pharmacologic effects of protease EC 24.11 inhibition.

Authors:  R L Webb; G D Yasay; C McMartin; R B McNeal; M B Zimmerman
Journal:  J Cardiovasc Pharmacol       Date:  1989-08       Impact factor: 3.105

8.  Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide.

Authors:  S Suga; K Nakao; K Hosoda; M Mukoyama; Y Ogawa; G Shirakami; H Arai; Y Saito; Y Kambayashi; K Inouye
Journal:  Endocrinology       Date:  1992-01       Impact factor: 4.736

9.  Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure: beneficial effects on left ventricular function.

Authors:  Y Saito; K Nakao; K Nishimura; A Sugawara; K Okumura; K Obata; R Sonoda; T Ban; H Yasue; H Imura
Journal:  Circulation       Date:  1987-07       Impact factor: 29.690

10.  Hydrolysis of alpha-human atrial natriuretic peptide in vitro by human kidney membranes and purified endopeptidase-24.11. Evidence for a novel cleavage site.

Authors:  Y Vanneste; A Michel; R Dimaline; T Najdovski; M Deschodt-Lanckman
Journal:  Biochem J       Date:  1988-09-01       Impact factor: 3.857

View more
  11 in total

1.  Effect of neutral endopeptidase inhibition on the natriuresis and renal clearance of atrial natriuretic peptide in perfused rat kidney.

Authors:  M Yamaguchi; Y Hashimoto; H Itoh; K Nakao; K Inui
Journal:  Pharm Res       Date:  1998-09       Impact factor: 4.200

Review 2.  Natriuretic peptide metabolism, clearance and degradation.

Authors:  Lincoln R Potter
Journal:  FEBS J       Date:  2011-04-07       Impact factor: 5.542

3.  Perioperative changes in plasma brain natriuretic peptide concentrations in patients undergoing cardiac surgery.

Authors:  K Morimoto; T Mori; S Ishiguro; N Matsuda; Y Hara; H Kuroda
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

4.  Natriuretic peptide-potentiating actions of neutral endopeptidase inhibition in rats with experimental heart failure.

Authors:  M Yasuhara; M Yamaguchi; H Shimizu; Y Hashimoto; N Hama; H Itoh; K Nakao; R Hori
Journal:  Pharm Res       Date:  1994-12       Impact factor: 4.200

Review 5.  C-type Natriuretic Peptide: A Multifaceted Paracrine Regulator in the Heart and Vasculature.

Authors:  Amie J Moyes; Adrian J Hobbs
Journal:  Int J Mol Sci       Date:  2019-05-08       Impact factor: 5.923

Review 6.  Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure.

Authors:  Lauren B Arendse; A H Jan Danser; Marko Poglitsch; Rhian M Touyz; John C Burnett; Catherine Llorens-Cortes; Mario R Ehlers; Edward D Sturrock
Journal:  Pharmacol Rev       Date:  2019-10       Impact factor: 25.468

7.  Soluble Neprilysin in the General Population: Clinical Determinants and Its Relationship to Cardiovascular Disease.

Authors:  Yogesh N V Reddy; Seethalakshmi R Iyer; Christopher G Scott; Richard J Rodeheffer; Kent Bailey; Gregory Jenkins; Anthony Batzler; Margaret M Redfield; John C Burnett; Naveen L Pereira
Journal:  J Am Heart Assoc       Date:  2019-07-26       Impact factor: 5.501

Review 8.  Cardiovascular Pleiotropic Effects of Natriuretic Peptides.

Authors:  Maurizio Forte; Michele Madonna; Sonia Schiavon; Valentina Valenti; Francesco Versaci; Giuseppe Biondi Zoccai; Giacomo Frati; Sebastiano Sciarretta
Journal:  Int J Mol Sci       Date:  2019-08-08       Impact factor: 5.923

Review 9.  The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment.

Authors:  Massimo Volpe; Marino Carnovali; Vittoria Mastromarino
Journal:  Clin Sci (Lond)       Date:  2016-01       Impact factor: 6.124

Review 10.  Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure.

Authors:  Shihui Fu; Ping Ping; Fengqi Wang; Leiming Luo
Journal:  J Biol Eng       Date:  2018-01-12       Impact factor: 4.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.